The US FDA has approved Inlyta (axitinib) for the treatment of advanced renal cell carcinoma, a type of kidney cancer, in patients with whom other drugs have not been effective, the FDA (Food and Drug Administration) announced today. Inlyta is made and marketed by pharmaceutical giant Pfizer Inc...Read original story